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Abstract 
The purpose of this study was to compare the effect of resistance training (RT) duration, 
including years of exposure, on agonist and antagonist neuromuscular activation throughout 
the knee extension voluntary torque range. Fifty-seven healthy men (untrained [UNT] n=29, 
short-term RT [12WK] n=14, and long-term RT [4YR] n=14) performed maximum and sub-
maximum (20-80% maximum voluntary torque [MVT]) unilateral isometric knee extension 
contractions with torque, agonist and antagonist surface EMG recorded. Agonist EMG, 
including at MVT, was corrected for the confounding effects of adiposity (i.e. muscle-electrode 
distance; measured with ultrasonography). Quadriceps maximum anatomical cross-sectional 
area (QACSAMAX; via MRI) was also assessed. MVT was distinct for all three groups (4YR 
+60/+39% vs. UNT/12WK; 12WK +15% vs. UNT; 0.001<P≤0.021), and QACSAMAX was 
greater for 4YR (+50/+42% vs. UNT/12WK; [both] P<0.001). Agonist EMG at MVT was 
+44/+33% greater for 4YR/12WK ([both] P<0.001) vs. UNT; but did not differ between RT 
groups. The torque-agonist EMG relationship of 4YR displayed a right/down shift with lower 
agonist EMG at the highest common torque (196 Nm) compared to 12WK and UNT 
(0.005≤P≤0.013; Effect size [ES] 0.90≤ES≤1.28). The torque-antagonist EMG relationship 
displayed a lower slope with increasing RT duration (4YR<12WK<UNT; 0.001<P≤0.094; 
0.56≤ES≤1.31), and antagonist EMG at the highest common torque was also lower for 4YR 
than UNT (-69%; P<0.001; ES=1.18). In conclusion, 4YR and 12WK had similar agonist 
activation at MVT and this adaptation may be maximised during early months of RT. In 
contrast, inter-muscular coordination, specifically antagonist co-activation was progressively 
lower, and likely continues to adapt, with prolonged RT. 
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Introduction 
Regular resistance training (RT) leads to increases in maximum strength, the maximum 
force/torque that can be produced by the trained musculature. These improvements in strength 
can increase the mobility of older adults 1, enhance athletic performance 2, reduce injury risk 3, 
and may decrease the likelihood of developing musculoskeletal disorders, such as osteoarthritis 
4. Consequently, regular and persistent RT is recommended for athletes, the general population, 
and older adults alike 5. Neural adaptations have been widely documented to contribute to the 
increases in strength following short-term RT (up to 14 weeks in duration; 6-9). It has often 
been assumed that changes in neuromuscular activation primarily occur in this initial short-
term period of RT with no/minimal further adaptations thereafter 10, although there is evidence 
that extensive neuroplasticity can occur in response to long-term RT 11-13. At present, however 
it is unclear if adaptations in neuromuscular activation continue to occur with prolonged RT 
(i.e. over several years) and might contribute to changes in function (strength). 
 
Surface electromyography (EMG) measurements have generally demonstrated 
increased neuromuscular activation of the agonist muscles at maximum torque after relatively 
short-term RT 7-9, although whether these adaptations in maximum agonist activation continue 
over longer periods of RT remains largely unexplored. Two longitudinal RT interventions with 
already highly resistance-trained men found no 14 or marginal 15 improvements in activation 
during isometric actions. Furthermore, Moritani and deVries 16 first proposed that changes in 
the full range of the torque-agonist EMG relationship may reveal useful information regarding 
the nature of underpinning physiological adaptations following RT. They hypothesised that 
changes in the position and extension of the torque-agonist EMG relationship after training 
could indicate neural (Fig. 1A), morphological (Fig. 1B), or a combination of both neural and 
morphological adaptations (Fig. 1 C) 16. Existing literature suggests an extension of the torque-
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agonist EMG relationship following 4 wk of RT 8,17 (e.g. Fig. 1A, neural adaptation), but a 
shift to the right with no extension after 8 wk to 6 mo of RT 18-20 (e.g. Fig. 1B, morphological, 
but no neural adaptation) which represents an incongruous time course of neural adaptations 
(increase and then decrease). Whilst it is likely the classic Moritani and DeVries model over 
simplifies the relative contribution of neural and morphological adaptations, the influence of 
more prolonged RT (i.e. for multiple years) on the torque-agonist EMG relationship has not 
been examined, and thus the time course of any changes remains unknown. In the first few 
months of RT the changes in strength appear to be primarily dependent on neural adaptations 
21 and thus a similar, but extended, torque-agonist EMG relationship may be expected (Fig. 
1A). Whereas with years of RT substantial hypertrophic, in addition to neural, adaptations are 
thought to occur 22 and the relationship may be expected to shift down/right, whilst extending 
to a similar maximum EMG as observed after short-term RT (Fig. 1C).  
 
Antagonist co-activation at maximum torque has been found to be unchanged 23, 
increased 24, and decreased 25 following short-term RT studies. These differences may be 
because antagonist co-activation is positively related to both torque and agonist activation, such 
that increased maximum torque and agonist activation after RT tend to cause an increase in 
antagonist co-activation, even if antagonist co-activation at the same torque has decreased 8. In 
which case the relationships between antagonist co-activation and torque/agonist activation 
may provide a more complete assessment. In fact, Tillin et al 8 found that after short-term RT 
co-activation was reduced at any absolute level of torque/agonist activation, even though co-
activation at maximum torque was unchanged, likely due to the increase in torque/agonist 
activation. However, whether prolonged RT, leads to further potentially more substantial 
adaptations in antagonist co-activation, beyond these short-term changes, is unclear. 
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Overall, it is unknown whether several years of RT causes continued adaptations in 
agonist activation and antagonist co-activation, and specifically changes the nature of the inter-
relationships between these neural variables and torque, beyond those documented by short-
term intervention studies. Whilst a longitudinal study of several years duration may be 
impractical, a comparison of groups with distinct durations of RT experience may facilitate 
investigation of these issues. Therefore, the purpose of the current investigation was to conduct 
a detailed comparison between untrained (UNT) vs. short-term RT (12 weeks [12WK]) vs. 
long-term RT (average 4 years [4YR]) men for agonist and antagonist neuromuscular 
activation throughout the voluntary torque range. The position of the torque-agonist EMG and 
torque-antagonist EMG relationships were assessed by determining their slope and also EMG 
amplitude at the highest common torque (i.e. the highest torque achieved by all participants). 
Based on limited existing evidence it was hypothesised that maximum agonist activation would 
be greater for 12WK vs. UNT, but with no further difference between 12WK and 4YR. It was 
also hypothesised that the torque-agonist EMG relationship, would: have a similar position, for 
12WK vs. UNT (Fig. 1A); have a down/rightwards position for 4YR vs. UNT and 12WK (Fig. 
1C). The final hypothesis was that antagonist co-activation at the same torque/agonist 
activation would progressively decrease with greater training duration (i.e. lower position of 
the torque-antagonist EMG relationship; 4YR<12WK<UNT). 
 
Materials and Methods 
Participants 
A total of fifty-seven young, healthy, asymptomatic, males provided written informed 
consent prior to participation in this study that was approved by the Loughborough University 
Ethical Advisory Committee. Physical activity levels of all participants were assessed with the 
International Physical Activity Questionnaire (IPAQ, short format; www.ipaq.ki.se). The UNT 
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group consisted of 29 participants (IPAQ: 2358 ± 1476 metabolic equivalent min/wk) who had 
not completed lower-body RT for >18 months and were not involved in systematic physical 
training. The 12WK group comprised 14 participants (IPAQ: 2097 ± 1303 metabolic 
equivalent min/wk) measured within a week of completing 12-weeks of supervised isometric 
knee extension RT (3 x/wk, 40 reps of 3 s at 75% maximum voluntary torque [MVT]), who 
were originally recruited from an identical population to the UNT group (i.e. no RT for >18 
months and not involved in any systematic physical training). Finally, the 4YR group consisted 
of 14 participants (IPAQ: 5568 ± 1457 metabolic equivalent min/wk) who reported (via a 
detailed questionnaire and follow-up oral discussion) systematic, progressive heavy RT of the 
quadriceps (i.e. completion of several knee extensor exercises within an individual session ~3 
x/wk typically consisting of: squat, lunge, step-up, and leg press) for ≥3 years (mean ± SD, 4 
± 1 years; range, 3-5 years) with the primary aim of developing maximum strength. The RT of 
this group had not been experimentally supervised although some of these participants had 
received variable coaching (technique and programming) support. Use of androgenic-anabolic 
steroids was an exclusion criterion for all participants. Many individuals in the 4YR group 
reported regular use of nutritional supplements (e.g. whey protein and creatine). 
 
Overview 
UNT, 12WK, and 4YR participants visited the neuromuscular laboratory for a 
familiarisation session involving isometric voluntary maximum and sub-maximum 
contractions. Thereafter, two duplicate neuromuscular measurement sessions were conducted 
on the dominant leg (7-10 days apart). Finally, MRI and ultrasound scans were performed 
within 7 days of the second neuromuscular measurement session. Neuromuscular measurement 
sessions were at a consistent time of day for each individual and started between 12:00-19:00. 
These sessions involved recordings of isometric knee extension/flexion torque and surface 
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EMG of the superficial quadriceps and hamstrings muscles during voluntary maximum and a 
range of sub-maximum contractions (20, 40, 60 and 80%). The primary outcome measures 
were maximum torque and simultaneous agonist and antagonist EMG, as well as the position 
of the torque-agonist EMG and torque-antagonist EMG relationships assessed by both 
relationship slope and EMG at the highest common torque. Whilst not primary outcomes the 
following measurements were also completed: (i) muscle size, assessed with a T1-weighted 
1.5T MRI scan of the thigh of each participant’s dominant leg (see “Muscle size” below); and 
(ii) muscle-electrode distance (MED) using B-mode ultrasonography at the sites where 
quadriceps EMG sensors were placed. Muscle size was included as an additional index of 
training status and morphological differences between the three groups. MED was measured 
to allow for the correction of the pronounced, confounding influence of subcutaneous tissue 
thickness, primarily body fat, on voluntary EMG amplitude 26. 
 
12WK supervised resistance training intervention 
All training sessions involved the same dynamometer and configuration used for the 
measurements (see below). After a brief warm-up of sub-maximum contractions of both legs, 
participants completed four sets of ten sustained unilateral isometric knee extension 
contractions of each leg; with sets alternating between dominant and non-dominant legs until 
4 sets per leg had been completed. Each set took 60 s with 2 min between successive sets on 
the same leg. This training model has been described extensively elsewhere 7 and was selected 
for the 12WK group within the current study as it has shown to produce increases in maximum 
strength during short-term RT interventions 7,8. Briefly, participants were presented with a 
target torque trace (on a computer monitor in front of them) 2 s before every contraction and 
were instructed to match this target trace, which increased torque linearly from rest to 
75%MVT over 1 s before holding a plateau at 75%MVT for a further 3 s. 12WK participants 
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performed three maximum voluntary isometric contractions (MVCs; see below) at the start of 
each training week to re-establish MVT and prescribe training torques. 12WK participants 
were instructed to maintain their habitual physical activity and diet throughout the 12-week 
training period. 
 
Torque and EMG recording 
Measurements were completed in a rigid custom-made isometric dynamometer with 
knee and hip angles of 115° and 126° (180° = full extension), respectively (as shown in Fig. 
6B of reference 27). Adjustable straps were tightly fastened across the pelvis and shoulders to 
prevent extraneous movement. An ankle strap (35 mm width reinforced canvas webbing) was 
placed ~15% of tibial length (distance from lateral malleolus to knee joint space), above the 
medial malleolus, and positioned perpendicular to the tibia and in series with a calibrated S-
beam strain gauge (Force Logic, Swallowfield, UK). The analogue force signal from the strain 
gauge was amplified (x370) and sampled at 2,000 Hz using an external A/D converter (Micro 
1401; CED Ltd., Cambridge, UK) and recorded with Spike 2 computer software (CED Ltd., 
Cambridge, UK). In offline analysis, force data were low-pass filtered at 500 Hz using a fourth-
order zero-lag Butterworth filter, gravity corrected by subtracting baseline force, and 
multiplied by lever length, the distance from the knee joint space to the centre of the ankle 
strap, to calculate torque values. 
Surface EMG was recorded from the superficial quadriceps (agonist EMG: rectus 
femoris [RF]; vastus lateralis [VL]; vastus medialis, [VM]) and hamstring muscles (antagonist 
EMG: biceps femoris [BF] and semitendinosus [ST]) using a wireless EMG system (Trigno; 
Delsys Inc., Boston, MA). Before single differential Trigno Standard EMG sensors (Delsys 
Inc., Boston, MA; fixed 1-cm interelectrode distance) were positioned skin preparation 
(shaving, abrading, and cleansing with 70% ethanol) was conducted. Individual sensors were 
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attached (using adhesive interfaces) at six separate sites over the superficial quadriceps muscles 
at set percentages of thigh length (above the superior border of the patella) as follows: RF 65 
and 55%; VL 60 and 55%; VM 35 and 30%. Similarly, individual sensors were placed on the 
BF and ST at 45% of thigh length above the popliteal fossa. Sensors were placed parallel to 
the presumed orientation of the underlying fibres. EMG signals were amplified at source (x300; 
20- to 450-Hz bandwidth) before further amplification (overall effective gain, x909), and 
sampled at 2,000 Hz via the same A/D converter and computer software as the force signal, to 
enable data synchronization. In offline analysis, EMG signals were corrected for the 48-ms 
delay inherent to the Trigno EMG system. 
 
Measurement sessions 
Following a brief warm-up of the dominant leg (3 s knee extension contractions at 50% 
[x3], 75% [x3], and 90% [x1] of perceived maximum) measurements were completed in the 
following order. 
 
Knee extension maximum voluntary contractions 
Participants performed 3-4 MVCs and were instructed to “push as hard as possible” for 
3-5 s and rest for ≥30 s between efforts. A torque-time curve with a horizontal cursor indicating 
the greatest torque obtained within that session was displayed for biofeedback and verbal 
encouragement was provided during all MVCs 7,8. Knee extensor MVT was the greatest 
instantaneous torque achieved during any MVC during that measurement session. Root mean 
square (RMS) EMG for a 500 ms epoch at MVT (250 ms either side) was calculated for each 
electrode site. RMS EMG from each quadriceps site was then averaged to provide an overall 
quadriceps EMG measurement during MVT production (agonist EMGMVT). RMS EMG from 
each of the hamstring sites during knee extension MVT (antagonist EMGMVT) was normalised 
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to that measured during knee flexion MVT (knee flexion EMGMAX; see below) and then 
averaged across the two hamstring sites. 
 
Knee extension sub-maximum voluntary contractions 
Horizontal cursors indicating four sub-maximum target torque levels were placed on 
the screen displaying the real-time torque-time curve and participants were instructed to 
gradually increase torque (over ~1 s) and match the prescribed torque level for ~5 s at 20, 40, 
60 or 80%MVT, performed in this order, with ≥30 s between efforts. From each recorded 
contraction, a 500 ms period of stable torque at approximately the prescribed level was 
identified and used to calculate mean knee extension torque. RMS EMG of each quadriceps 
and hamstring EMG site was measured for each of these epochs. 
 
Knee flexion maximum voluntary contractions 
Knee flexion MVCs were performed in the same manner as knee extension, except 
participants performed a series of sub-maximum knee flexion efforts to warm-up and were 
instructed to “pull as hard as possible” for 3-5 s, rather than “push” 8,21. Knee flexion MVT 
was the greatest instantaneous torque achieved during any MVC during that measurement 
session. RMS hamstring EMG for a 500 ms epoch at knee flexion MVT (250 ms either side) 
was analysed for each site (knee flexion EMGMAX). 
 
Muscle size 
A 1.5T MRI scan of the dominant leg was made in the supine position at a knee joint 
angle of ~163° using a receiver 8-channel whole body coil (Signa HDxt, GE). T1-weighted 
axial slices (5 mm thick, 0 mm gap) were acquired from the anterior superior iliac spine to the 
knee joint space in two overlapping blocks. Oil filled capsules placed on the lateral side of the 
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participants’ thigh allowed alignment of the blocks during analysis. MR images were analysed 
by two trained investigators using Osirix software (version 6.0, Pixmeo, Geneva, Switzerland). 
The quadriceps (RF, VL, VM, and vastus intermedius; VI) muscles were manually outlined in 
every third image (i.e. every 15 mm) starting from the most proximal image in which the 
muscle appeared. The image with the largest anatomical cross-sectional area (ACSA) was 
defined as the maximum ACSA for each individual quadriceps muscle and the sum of the 
muscles was defined as maximum quadriceps ACSA (QACSAMAX). 
 
Muscle-electrode distance and correction of agonist EMG. 
 Images of the distance between the skin surface and the peripheral surface of the muscle 
at each of the six sites where quadriceps EMG sensors were positioned (i.e. muscle-electrode 
distance, MED) were collected using a B-mode ultrasonography machine (EUB-8500, Hitachi 
Medical Systems UK Ltd, Northamptonshire, UK) with a 9.2 cm wide linear-array transducer 
(EUP-L53L), sampling at 32 Hz, interfaced with a personal computer operating ezcap video 
capture software. The transducer was coated with water-soluble transmission gel and placed 
perpendicular to the skin over the RF, VL, and VM at the percentages of thigh length listed 
above for each quadriceps EMG sensor. Images were later imported in to a public domain 
software (Tracker version 4.92; www.cabrillo.edu/~dbrown/tracker) and MED was measured 
by one trained investigator. 
 
When agonist EMG data for all participants was pooled (i.e. n= 57) there were inverse 
relationships between absolute EMG amplitude and MED for all sensor locations and all types 
of contraction (maximum and all sub-maximum levels; Pearson’s product moment bivariate 
correlations, -0.670 ≤ r ≤ -0.394; 0.001<P≤0.002). Additionally, when comparing the three 
groups MED differed or tended to differ (One-way ANOVA 0.014≤P≤0.070) with several 
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“Moderate” to “Large” effect sizes (0.71≤ES≤1.03) between groups at three out of six sites. 
Consequently, all individual agonist EMG measurements were corrected for MED at the 
corresponding site, using the quadratic relationship between agonist EMG amplitude and MED 
at that specific measurement site. Correcting EMG amplitude measurements for the amount of 
subcutaneous tissue at the recording site 28 or using MED as a covariate within statistical testing 
29 are approaches that have previously been employed. The MED correction in the current study 
involved summating the individual’s residual absolute agonist EMG amplitude, in comparison 
to the cohort relationship with MED (e.g. agonist EMG amplitude vs. MED), with the pooled 
group mean for absolute agonist EMG amplitude 26. Overall corrected agonist EMG during all 
maximum and sub-maximum contractions was then calculated by averaging the corrected 
EMG amplitude measurements from each EMG recording site.  
 
Data analysis and statistics 
All torque and EMG measurements from the two neuromuscular measurement sessions 
were averaged to produce criterion values. Bivariate relationships were then analysed with 
Pearson’s product moment correlation. Only agonist EMG values corrected for MED were 
used for establishing relationships. Three relationships were plotted and assessed for each 
individual participant: knee extension torque vs. corrected agonist EMG; knee extension torque 
vs. normalised antagonist EMG; and normalised antagonist EMG vs. corrected agonist EMG. 
Relationships were fitted with linear functions, but not forced through zero as forcing the 
function through zero significantly reduced the R2 values of all three relationships (paired t-
test, [all] P<0.001). The position of the torque-agonist EMG and torque-antagonist EMG 
relationships were assessed with: (i) relationship slope (‘m’ constant of the linear function) and 
(ii) EMG at the highest common torque achieved by all participants (196 Nm, equivalent to the 
MVT of the weakest participant and indicated as a vertical dotted line in Fig. 3A and B). EMG 
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values for each participant at the highest common torque were derived by solving the individual 
linear function (for an x axis value of 196 Nm) for the relationship between isometric knee 
extension torque and either agonist or antagonist EMG. The slope of the antagonist EMG-
agonist EMG relationship was also calculated. 
All statistical analyses were performed using SPSS Version 24.0 (IBM Corp., Armonk, 
NY). Data are reported or displayed as means ± SD, except in figures displaying EMG 
relationships where for presentation purposes data points with x and y error bars to the far right 
of the figure display average SD for the five load increments across the voluntary torque range 
for each group. One-way ANOVAs were conducted as the main statistical tests to assess if 
differences existed between groups for: descriptive characteristics (i.e. age, height, and body 
mass); agonist EMGMVT; antagonist EMGMVT; the slope derived from the relationships (i.e. 
torque-agonist EMG, torque-antagonist EMG, antagonist EMG-agonist EMG); and agonist 
EMG and antagonist EMG at the highest common knee extension torque. When one-way 
ANOVAs displayed P<0.05, a combined post-hoc criteria involving both a least significant 
difference (LSD) P value of <0.10 and an effect size (ES) >0.50 were required for there to be 
considered good evidence of between-group differences. LSD P values were stepwise corrected 
for multiple comparisons and ES was calculated as previously detailed for between-subject 
study designs 7 and classified as follows: <0.20 “Trivial,” 0.20 – 0.49 “Small,” 0.50 – 0.80 
“Moderate,” or >0.80 “Large”. 
 Between-test session reliability of key measurements was assessed by pooling all three 
groups of participants (i.e. n= 57) using: (i) within-participant coefficient of variation (CVW, 
[SD/mean] × 100) as a measure of absolute reliability; and (ii) intra-class correlation coefficient 
(ICC; two-way mixed, absolute agreement) to assess relative reliability. CVW values were 
interpreted as “acceptable” <12%, “intermediate” 12–20%, or “unacceptable” >20%. ICC 
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values were interpreted as ‘‘very high’’ 0.90–1.00, ‘‘high’’ 0.70–0.89, “moderate” 0.50–0.69, 
“low” 0.30–0.49, “negligible” 0.00–0.29. 
 
Results 
Between-test session reliability 
 Knee extension and knee flexion MVT returned mean CVW values of 2.7% and 10.8% 
and ICC values of 0.980 and 0.889, respectively. Absolute agonist and antagonist EMG at knee 
extension MVT demonstrated mean CVW values of 8.8% and 17.8% and ICC values of 0.937 
and 0.774, respectively. Agonist EMG corrected for MED and normalised antagonist EMG 
(both) at knee extension MVT produced mean CVW values of 8.3% and 25.8% and ICC values 
of 0.876 and 0.790, respectively. 
 
Descriptive characteristics, muscle strength and size 
Age, height, and body mass were similar for 12WK (24 ± 2 y; 1.75 ± 0.08 m; 70 ± 9 
kg) and UNT (25 ± 2 y; 1.76 ± 0.07 m; 74 ± 10 kg) groups ([all variables] LSD P≥0.247). The 
4YR group were younger (22 ± 2 y), taller (1.84 ± 0.06 m), and heavier (92 ± 10 kg) than the 
other two groups ([all variables] LSD P≤0.004). Knee extension MVT of 12WK (293 ± 49 
Nm) was 15% greater than UNT (255 ± 42 Nm; LSD P=0.021; ES=0.86 “Large”), whilst MVT 
of 4YR (407 ± 63 Nm) was 60% greater than UNT and 39% greater than 12WK ([both] 
P<0.001; 2.02≤ES≤3.07 [both] “Large”; Fig. 2A). Knee flexion MVT of 4YR (104 ± 21 Nm) 
was 72% greater than UNT (61 ± 23 Nm; LSD P<0.001; ES=1.91 “Large”) and 63% greater 
than 12WK (64 ± 15 Nm; P<0.001; ES=2.19 “Large”), but no differences in knee flexion MVT 
occurred between 12WK and UNT (P=0.636; ES=0.16 “Trivial”). QACSAMAX of 4YR was 
50% greater than UNT and 42% greater than 12WK ([both] LSD P<0.001; 2.78≤ES≤3.63 
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[both] “Large”); but did not differ between 12WK and UNT (P=0.204; ES=0.42 “Small”; Fig. 
2B). 
 
Absolute agonist and antagonist EMG at knee extension maximum voluntary torque 
Absolute agonist EMGMVT was greater for 4YR (+66%; LSD P<0.001; ES= 1.53 
“Large”) and 12WK (+32%; P=0.050; ES=0.78 “Moderate”) compared to UNT (Table 1). In 
addition, absolute agonist EMGMVT was greater for 4YR than 12WK (+25%; LSD P=0.048; 
ES=0.72 “Moderate”; Table 1). In contrast, there were no statistical differences between groups 
for absolute antagonist EMGMVT (Table 1). 
 
Corrected agonist and normalised antagonist EMG at knee extension maximum voluntary 
torque 
 Agonist EMGMVT (corrected for MED) was greater for both 4YR (+44%; LSD 
P<0.001; ES=1.73 “Large”) and 12WK (+33%; P<0.001; ES=1.29 “Large”) than UNT; but 
was not statistically different between the two RT groups (P=0.281; ES=0.35 “Small”; Fig. 2C 
and Table 1). Normalised antagonist EMG at knee extension MVT was not different between 
groups (Table 1).  
 
Knee extension torque-agonist EMG relationship 
The torque-agonist EMG relationship was well represented by a linear function with 
high R2 values for all three groups regardless of RT experience (4YR, 0.978 ± 0.026; 12WK, 
0.970 ± 0.054; UNT, 0.972 ± 0.066). There were no differences between the groups for slope 
of the torque-agonist EMG relationship (Table 1; Fig. 3A). However, agonist EMG at the 
highest common torque (196 Nm) was lower for 4YR compared to UNT (-24%; LSD P=0.013; 
ES=0.90 “Large”) and 12WK (-30%; P=0.005; ES=1.28 “Large”) indicating a downward shift 
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in the torque-agonist EMG relationship (Fig. 4A). No differences in agonist EMG at 196 Nm 
occurred between 12WK and UNT (LSD P=0.296; ES=0.35 “Small”; Fig. 4A). 
 
Knee extension torque-antagonist EMG relationship  
The torque-antagonist EMG relationship was well represented by a linear function with 
high R2 values regardless of RT experience (4YR, 0.971 ± 0.020; 12WK, 0.952 ± 0.043; UNT, 
0.894 ± 0.111). The slope of the knee extension torque-antagonist EMG relationship differed 
between all three groups (Table 1), being lower for 12WK than UNT (-30%; LSD P=0.061; 
ES=0.56 “Moderate”), and lower for 4YR than 12WK (-52%; P=0.094; ES=1.22 “Large”) or 
UNT (-66%; P<0.001; ES=1.31 “Large”; Fig. 3B and Table 1). Antagonist EMG at 196 Nm of 
knee extension torque was lower for 4YR compared to UNT (-69%; LSD P<0.001; ES=1.18 
“Large”; Fig. 4B and Table 1) but not vs. 12WK (P=0.108; ES=1.23 “Large”). No differences 
in antagonist EMG at 196 Nm occurred for 12WK compared to UNT (LSD P=0.120; ES=0.46 
“Small”; Fig. 4B). 
 
Antagonist EMG-Agonist EMG relationship during knee extension contractions 
The slope of the antagonist EMG-agonist EMG relationship was lower for both 4YR (-
59%; LSD P<0.001; ES=1.22 “Large”) and 12WK (-37%; P=0.028; ES=0.77 “Moderate”) vs. 
UNT (Fig. 5 and Table 1). The 12WK group appeared to occupy an intermediate position 
between the other two groups although there was no difference between the slopes of the two 
trained groups (12WK vs. 4YR; LSD P=0.202; ES=0.69 “Moderate”; Fig. 5). High R2 values 
for the antagonist EMG-agonist EMG relationship were displayed for all groups regardless of 
RT experience (4YR, 0.982 ± 0.012; 12WK, 0.972 ± 0.031; UNT, 0.892 ± 0.135). 
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Discussion 
 The purpose of this study was to compare neuromuscular activation of the agonist and 
antagonist musculature during knee extension contractions throughout the voluntary torque 
range between long-term RT (4YR), short-term RT (12WK) and untrained (UNT) groups. In 
agreement with our hypothesis, maximum agonist activation (corrected for MED) was higher 
for both RT groups than UNT, but did not differ between 12WK and 4YR. As hypothesised, 
the torque-agonist EMG relationship for 12WK had a similar position to UNT (slope and 
agonist EMG at 196 Nm), for 4YR occupied a lower position than the other two groups (lower 
agonist EMG at 196 Nm), although the slope was similar for all groups. The position of the 
torque-antagonist EMG relationship also showed distinct differences between groups with 
lower slope according to RT duration (4YR<12WK<UNT) and lower antagonist EMG at the 
highest common knee extension torque for 4YR vs. UNT. Based on these findings it appears 
that changes in maximum agonist activation predominantly occur in the first weeks of RT, but 
not substantially thereafter, although the 4YR RT group displayed a down/rightwards position 
of the torque-agonist EMG relationship presumably due to substantial hypertrophy. In contrast, 
the lower antagonist co-activation for 4YR than 12WK, evidenced by differences in the slope 
of the torque-antagonist EMG relationship, suggests that inter-muscular co-ordination may be 
the primary long-term neural adaptation to RT. 
 
 The greater agonist activation (both absolute EMG and corrected for MED) at 
maximum voluntary torque of both RT groups compared to the untrained cohort supports 
numerous previous reports that agonist activation increases following RT 7-9, although some 
older studies have reported no change in agonist EMG amplitude after RT 18,19. Moreover, the 
greater neuromuscular activation (maximum agonist EMG) of 12WK vs. UNT, coupled with 
the similar muscle size of these groups supports the concept that strength gains following short-
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term RT result predominantly from neural adaptations 10,16. In fact, we recently found the 
largest determinant of the change in strength following 12-weeks of RT to be the increase in 
agonist neuromuscular activation (EMG), explaining 30.6% of the variance in strength gains 
21. The greater agonist neuromuscular activation of 12WK vs. UNT may be due to increased 
motor unit firing rate 30 and/or recruitment of additional motor units 31, but these mechanisms 
were not discernible from the current EMG amplitude measurements. Whilst absolute agonist 
EMG also showed differences between the two RT groups (12WK vs. 4YR) this appeared to 
be in part due to the lower MED of the 4YR group, as there were no differences in agonist 
EMG amplitude between the two RT cohorts, once corrected for MED. Overall, these findings 
suggest that maximum agonist activation increases in the first 12 weeks of RT, but does not 
continue to adapt beyond 12 weeks of RT (up to ~4 years). 
 
The consistent position, but extended, torque-agonist EMG relationship of 12WK 
compared to UNT in the current cross-sectional study was in agreement with short-term 
longitudinal RT studies 8,17. The lower agonist EMG at the highest common torque of the 4YR 
group (vs. UNT or 12WK) confirmed the visual impression that the torque-agonist EMG 
relationship was positioned further to the right for this group, despite the observation that the 
slope of the torque-agonist EMG relationship was similar for all three groups. The longest 
intervention studies we are aware of reported a qualitative reduction in the slope of the torque-
agonist EMG relationship after 6 months of RT 19,20, which is broadly supportive of the 
observation that the position of the relationship is adaptable and shifts down/right with 
prolonged RT. A logical explanation of the 4YR group’s lower agonist EMG amplitude to 
produce the same knee extension torque, and thus the subsequent down/rightwards position of 
the torque-agonist EMG relationship of this group, is substantial hypertrophy 16 and/or possible 
greater neuromuscular efficiency 32. Indeed, the 4YR group had considerably larger quadriceps 
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than the other two groups (+42/+50% greater QACSAMAX vs. 12WK/UNT). Hypertrophied 
muscle would be expected to require activation of fewer, but larger, fibres to achieve the same 
torque production and hence lower agonist EMG. 
 
Antagonist EMG amplitude at knee extension MVT was not different between groups, 
despite 4YR having 28-38% lower normalised antagonist EMG than the other groups. 
Measurements of antagonist EMG amplitude at MVT are likely confounded by the differences 
in MVT between groups, which demonstrably effects antagonist EMG via the extremely strong 
torque-antagonist EMG relationship we have described (R2>0.89), as well as the large 
variability in this measurement 8, and these issues probably explain the confused findings for 
antagonist co-activation at MVT within the literature 23-25. In this case the position of the 
relationships between antagonist EMG and torque/agonist EMG or antagonist EMG at a 
common torque level may be a more reliable and meaningful measures of antagonist co-
activation. In fact, the slope of the torque-antagonist EMG relationship was distinct between 
all three groups (4YR<12WK<UNT), being ~two-thirds less steep for 4YR than UNT. 
Similarly, antagonist EMG at the highest common knee extension torque was also substantially 
lower for 4YR than UNT (-69%), and even though not significantly different comparably large 
differences were demonstrated between 4YR vs 12WK (-57%). Finally, the agonist-antagonist 
activation relationship appeared visually to show distinct and progressively lower positions 
according to RT duration, but only revealed differences for both RT groups vs. UNT. Overall, 
these findings provide convincing evidence that antagonist co-activation shows substantial 
scope for continued adaptation beyond the first 12 weeks of training, and thus may be the 
primary long-term neural adaptation to RT. 
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The finding that antagonist co-activation was progressively lower as a function of RT 
duration (i.e. slope of torque-antagonist EMG relationship: UNT>12WK>4YR), despite there 
being no difference in maximum agonist activation between groups with 12 weeks or ~4 years 
of RT experience, indirectly supports cortical excitability and spinal reflex response research 
suggesting that agonist and antagonist activation are modulated by different supraspinal 
mechanisms 33. Whilst our understanding of the precise mechanisms (i.e. supraspinal and/or 
spinal) that modulate antagonist co-activation is still incomplete 34, the progressive decrease in 
antagonist co-activation across the three groups with increasing RT experience in the current 
study indicates that with prolonged RT (up to ~4 years) antagonist co-activation likely 
contributes to increased strength due to reduced antagonist knee flexion torque. It would be 
highly interesting to be able to accurately translate these apparent changes in antagonist 
neuromuscular activation to quantitative changes in antagonist torque, however this is 
problematic for several reasons: we have assessed co-activation of only two of nine knee flexor 
muscles; such a calculation would require the agonist EMG-knee flexion torque relationship 
of all these muscles; which is itself confounded by antagonist quadriceps activation. 
Nonetheless, on a relatively simplistic level, assuming a linear knee flexion torque-agonist 
EMG relationship in order to calculate antagonist knee flexion torque (i.e. % normalised 
antagonist EMG x knee flexion MVT) at the common knee extensor torque of 196 Nm, reveals 
antagonist torque for UNT of 11.6 Nm (19.0% x 61 Nm), 8.8 Nm for 12WK (13.7% x 64 Nm) 
and 6.1 Nm for 4YR (5.9% x 104 Nm). The observation that maximum agonist neuromuscular 
activation was similar for 12WK compared to 4YR, whilst antagonist co-activation showed 
some marked but functionally small differences between these groups, strongly supports the 
notion that other adaptations, primarily morphological changes, such as the 4YR group’s 
substantial hypertrophy (QACSAMAX: +42% vs. 12WK), is the primary explanation for their 
much greater strength (MVT: +114 Nm vs. 12WK). 
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Given the practical issues with implementing supervised RT interventions for multiple 
years the results of the current study provide novel insight in to how the human neuromuscular 
system likely adapts with continued RT. Nonetheless it is important to consider the limitations 
of the current study. The cross-sectional design clearly provides a weaker level of evidence 
than longitudinal intervention studies, and make it impossible to fully discern the contribution 
of selection (i.e. innate differences [nature]), as opposed to the influence of RT (nurture), which 
is the primary question of this research. For example, it is conceivable that individuals attracted 
to regular prolonged RT (i.e. the 4YR group), are innately stronger, perhaps due to specific 
neuromuscular differences conceivably including better inter-muscular co-ordination, than the 
normal population. Nonetheless, whilst the 4YR group were clearly selected for their 
characteristic RT history, and thus were by definition distinct from the normal population, this 
was not the case for the 12WK group that were initially recruited from an identical population 
as the UNT group with only a minor proportion randomly assigned to the 12WK RT 
intervention. Thus, within the current findings when there is a clear progression across the 
groups (i.e. UNT>12WK>4YR as for the slope of the torque-antagonist EMG relationship) we 
can be more confident that this was not due to selection bias, but in all probability due to the 
duration of RT. In addition, when there are no differences between groups (e.g. 4YR vs. 12WK 
as for corrected agonist EMG during MVT) it seems likely that RT duration does not have a 
pronounced effect. 
 
Although both the 12WK and 4YR groups were performing heavy RT, the contraction 
modes employed were different between the two groups (i.e. 12WK: isometric RT; 4YR: 
concentric and eccentric RT). It is possible that the task specific training of the 12WK group 
(isometric training specific to isometric testing) might have produced task-specific neural 
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adaptations 7, which was not the case for the 4YR group, and thus accentuated task-specific 
adaptations of 12WK may have minimised the neural differences between these two groups. 
In this case the neural, and potentially also strength, differences that we have documented 
between 12WK and 4YR may well have been more pronounced given identical RT modes. 
Nonetheless the pronounced differences in strength between these groups appeared to be 
primarily due to morphological differences, rather than similar corrected agonist activation or 
functionally small differences in antagonist co-activation between the groups. Moreover, 
multiple-year longitudinal RT intervention studies employing contemporary EMG techniques, 
careful antagonist EMG-torque/agonist EMG relationships, and measurements at multiple 
intervals throughout the course of the intervention are required to confirm the findings we 
report here. Whilst we considered including the interpolated twitch technique in the current 
study, it was excluded due to several studies demonstrating its limited sensitivity to detect 
changes in activation after RT 8,35,36. 
 
It should also be noted that the results of the present investigation could be specific to 
the knee joint and the open kinetic chain knee extension task that was used. Further thorough 
investigations of agonist, antagonist, and stabiliser muscle activation during other single-joint 
and also multiple-joint and/or multiplanar strength tasks are necessary to gain greater 
understanding of the nature of neural adaptations to long-term RT. The limitations of surface 
EMG measurements have been widely documented and may not provide an ideal index of the 
neural drive to the muscle 37. For example, the size of the surface action potential has been 
found to be only moderately associated with motor unit size 38. In addition, it is possible that 
amplitude cancellation (i.e. when positive and negative phases of concurrent action potentials 
overlap and reduce the sum of the surface EMG measurement) could have influenced the 
results of the current study 39, especially given there is evidence that increased motor unit 
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synchronisation can occur following RT 11,40. Therefore, it is recommended that future work 
utilise other techniques (e.g. EMG decomposition, transcranial magnetic stimulation) to better 
understand the changes in muscle activation with prolonged RT. 
 
In conclusion, it appears that maximum agonist activation changes predominantly occur 
in the first weeks of RT (up to 12 wk), but not substantially thereafter, although long-term RT 
(up to ~4 years) led to a rightwards shift of the torque-agonist EMG relationship presumably 
due to the substantial hypertrophy of these participants. Interestingly, antagonist co-activation 
was progressively lower according to RT duration suggesting that inter-muscular co-ordination 
may be the primary long-term neural adaptation to RT. Multiple-year longitudinal RT 
intervention studies employing appropriate neural measurements at multiple intervals 
throughout the course of the intervention are required to confirm the cross-sectional findings 
observed in the present investigation. 
 
Perspectives 
 Prior to this study it was largely unexplored whether several years of resistance training 
(RT) causes continued adaptations in agonist activation and antagonist co-activation beyond 
short-term RT, although Moritani & DeVries (1979) hypothesised specific changes in the 
torque-agonist EMG relationship according to neural (short-term) and hypertrophic (long-
term) adaptations. Differences in agonist activation were broadly as speculated by Moritani & 
DeVries (1979) with greater maximum agonist activation after short-term, but without further 
changes after long-term RT, and a rightwards shift in the torque-agonist activation relationship 
only after long-term RT. In addition, it was particularly interesting that there was lower co-
activation of the antagonist muscles according to RT duration that suggests continued 
improvements in inter-muscular co-ordination. The findings of the current investigation have 
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potential implications for the practices and physiological understanding of individuals 
prescribing and/or undertaking long-term RT. Future research in this area is clearly warranted 
to investigate the influence of long-term (multiple-year) RT interventions on agonist, 
antagonist, and stabiliser neuromuscular activation during diverse mechanical tasks/conditions 
(including isometric and isoinertial, and single- and multiple-joint and/or multiplanar strength 
tasks). 
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FIGURE CAPTIONS 
 
Fig. 1 Illustration of pre- to post-training changes in the torque-agonist EMG relationship 
considered to be representative of: (A) exclusively neural adaptations (unchanged slope but 
extended relationship with a right and upward shift of the maximum point; (B) exclusively 
hypertrophic adaptations (lower slope with the maximum point shifted to the right); (C) a 
combination of neural and hypertrophic adaptations (lower slope, but with a maximum point 
shifted to the right and upwards). Adapted from Moritani and deVries 16. 
 
Fig. 2 (A) Knee extension maximum voluntary torque; (B) quadriceps maximum anatomical 
cross-sectional area (QACSAMAX); and (C) agonist EMG amplitude (corrected for muscle-
electrode distance) of untrained (UNT), short-term resistance-trained (12WK), and long-term 
resistance-trained (4YR) groups. Data are mean ± SD. Symbols indicate differences between 
groups: * greater than UNT; † greater than 12WK. 
 
Fig. 3 The relationship between torque and (A) agonist EMG amplitude (corrected for muscle-
electrode distance) and (B) normalised antagonist EMG throughout the knee extension 
voluntary torque range for untrained (UNT), short-term resistance-trained (12WK), and long-
term resistance-trained (4YR) groups. Data points to the far right of Fig. 3A and B display x 
and y error bars that are the mean SD for torque (x error bars) and EMG amplitude (y error 
bars) for the five load increments across the voluntary torque range for each group. Knee 
Flexion EMGMAX, agonist EMG during isometric knee flexion maximum voluntary torque. 
 
Fig. 4 (A) Agonist EMG amplitude (corrected for muscle-electrode distance); and (B) 
normalised antagonist EMG at the highest common isometric knee extension torque achieved 
by all participants (196 Nm; derived by solving individual linear equations) for untrained 
(UNT), short-term resistance-trained (12WK), and long-term resistance-trained (4YR) groups. 
Data are mean ± SD. Symbols indicate differences between groups: * lower than UNT; † lower 
than 12WK. Knee Flexion EMGMAX, agonist EMG during isometric knee flexion maximum 
voluntary torque. 
 
Fig. 5 The relationship between agonist EMG amplitude (corrected for muscle-electrode 
distance) and normalised antagonist EMG throughout the knee extension voluntary torque 
range for untrained (UNT), short-term resistance-trained (12WK), and long-term resistance-
trained (4YR) groups. Data points to the far right of the figure display x and y error bars that 
are the mean SD for agonist EMG (x error bars) and antagonist EMG (y error bars) amplitude 
for the five load increments across the voluntary torque range for each group. Knee Flexion 
EMGMAX, agonist EMG during isometric knee flexion maximum voluntary torque. 
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TABLES 
 
Table 1. Agonist and antagonist surface EMG amplitudes and the slope of the relationship between agonist EMG and torque/antagonist EMG for untrained 
(UNT), short-term resistance-trained (12WK), and long-term resistance-trained (4YR) groups. 
 
  UNT (n=29) 12WK (n=14) 4YR (n=14) ANOVA P value 
         
Activation at MVT:        
Absolute agonist EMG (mV) 0.182 ± 0.073 0.241 ± 0.081* 0.301 ± 0.087*† <0.001 
Absolute antagonist EMG (mV) 0.019 ± 0.009 0.020 ± 0.007 0.016 ± 0.008 0.540 
         
Corrected agonist EMG (mV) 0.192 ± 0.042 0.255 ± 0.061* 0.277 ± 0.060* <0.001 
Normalised antagonist EMG (% Knee flexion EMGMAX) 23.1 ± 14.0 20.0 ± 10.0 14.4 ± 10.9 0.107 
         
Activation at highest common torque (196 Nm)      
Corrected agonist EMG (mV) 0.151 ± 0.039 0.164 ± 0.039 0.116 ± 0.040*† 0.004 
Normalised EMG (% Knee flexion EMGMAX) 19.0 ± 13.2 13.7 ± 7.8 5.9 ± 4.5* 0.001 
         
Slope of linear relationship:        
Torque (Nm)-Corrected agonist EMG (mV) 8.163 ± 2.186 x 10-4 9.280 ± 2.578 x 10-4 7.507 ± 2.461 x 10-4 0.138 
Torque (Nm)-Normalised antagonist EMG (% Knee flexion EMGMAX) 0.109 ± 0.065 0.077 ± 0.041* 0.037 ± 0.023*† <0.001 
Normalised antagonist EMG (% Knee flexion EMGMAX)-Corrected agonist EMG (mV) 132 ± 72 83 ± 41* 54 ± 43* <0.001 
 
Data are mean ± SD. One-way ANOVAs and subsequent post-hoc tests were used to establish differences between groups. Symbols indicate differences between groups: * Different than 
UNT; † Different than 12WK. Knee flexion EMGMAX, agonist EMG during isometric knee flexion maximum voluntary torque. Corrected agonist EMG was calculated by using the quadratic 
relationship between EMG amplitude and muscle-electrode distance for all participants (n=57) on a sensor and contraction intensity specific basis before averaging across sites to derive overall 
agonist EMG measurements. 
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